AngioDynamics (NASDAQ: ANGO) Soars on Strong Q4 Results and Raised Price Target

• H.C. Wainwright raised its price target for AngioDynamics (NASDAQ: ANGO) to $19 from $16, maintaining a Buy rating.
• The medical technology company reported an 8% year-over-year revenue increase to $86.6 million in Q4, driven by its Med Tech division's 16.7% sales climb.
• AngioDynamics forecasts fiscal year 2027 sales between $336 million and $341 million, with the stock reaching a new 52-week high of $14.80.

AngioDynamics (NASDAQ: ANGO) is a leading medical technology company that focuses on improving patient lives. It develops innovative devices for restoring healthy blood flow and expanding cancer treatment options. Esteemed analyst firm H.C. Wainwright maintains its Buy rating for AngioDynamics, signaling strong confidence in the company's strategic direction and robust performance.

This positive outlook is clearly reflected in H.C. Wainwright raising its price target for AngioDynamics to $19 from a previous target of $16. A price target is an analyst's projection of a stock's future price. This optimistic decision follows the company's strong fourth-quarter results, which showcased an impressive 8% yearly revenue increase to $86.6 million.

The significant revenue growth is primarily driven by AngioDynamics' Med Tech division, which saw sales climb by a substantial 16.7%. As highlighted by Zacks.com, this surge was led by its flagship NanoKnife and AlphaVac products. Sales for these key products grew significantly, with NanoKnife up by 64.5% and AlphaVac up by 38.4% respectively, underscoring their market demand and effectiveness.

As noted in its earnings call on marketbeat.com, President and CEO Jim Clemmer credits "consistent execution across the business" for these outstanding results. The company is not only delivering "above-market profitable growth" but also expanding its ability to generate positive cash flow. This strong operational execution further supports the firm's positive rating and future prospects.

Looking ahead, AngioDynamics forecasts fiscal year 2027 sales between $336 million and $341 million, indicating continued growth. The market has responded exceptionally well to these developments, with the stock hitting a new 52-week high of $14.80. The company currently boasts a market capitalization of about $594.62 million, which represents the total value of all its outstanding shares, reflecting its solid market position.